Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106160 | 1.00 | THRB (0.43) | THRBALOX15SMN1; SMN2NFE2L2 | |
| SCHEMBL10110594 | 0.77 | SMN1; SMN2 (0.48) | THRBALOX15SMN1; SMN2NFE2L2 | |
| SCHEMBL10110367 | 0.77 | SMN1; SMN2 (0.48) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL16369092 | 0.77 | SMN1; SMN2 (0.48) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL10119628 | 0.77 | SMN1; SMN2 (0.48) | THRBALOX15SMN1; SMN2NFE2L2 | |
| SCHEMBL11126181 | 0.77 | SMN1; SMN2 (0.38) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL12757886 | 0.76 | SMN1; SMN2 (0.41) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL12757887 | 0.76 | SMN1; SMN2 (0.41) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL12757898 | 0.76 | SMN1; SMN2 (0.41) | THRBALOX15SMN1; SMN2 | |
| SCHEMBL12758002 | 0.72 | SMN1; SMN2 (0.34) | THRBALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157403-A1 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS | CHACKALAMANNIL SAMUEL (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157403-A1 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS | CHACKALAMANNIL SAMUEL (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153664-B2 | thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer | SCHERING CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| US-20080090830-A1 | Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090830-A1 | Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists | EDNRB, TBXA2R, BDKRB1 | THRB 16/4885ALOX15 755/4885SMN1; SMN2 4159/4885 |
| US-20120157403-A1 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS | EDNRB, TBXA2R, BDKRB1 | THRB 16/4885ALOX15 784/4885SMN1; SMN2 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.